» Articles » PMID: 15520185

The SmoA1 Mouse Model Reveals That Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-induced Medulloblastomas

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Nov 3
PMID 15520185
Citations 222
Authors
Affiliations
Soon will be listed here.
Abstract

To develop a genetically faithful model of medulloblastoma with increased tumor incidence compared with the current best model we activated the Sonic Hedgehog (Shh) pathway by transgenically expressing a constitutively active form of Smoothened in mouse cerebellar granule neuron precursors (ND2:SmoA1 mice). This resulted in early cerebellar granule cell hyper-proliferation and a 48% incidence of medulloblastoma formation. Gene expression studies showed an increase in the known Shh targets Gli1 and Nmyc that correlated with increasing hyperplasia and tumor formation. Notch2 and the Notch target gene, HES5, were also significantly elevated in Smoothened-induced tumors showing that Shh pathway activation is sufficient to induce Notch pathway signaling. In human medulloblastomas reverse transcription-PCR for Shh and Notch targets revealed activation of both of these pathways in most tumors when compared with normal cerebellum. Notch pathway inhibition with soluble Delta ligand or gamma secretase inhibitors resulted in a marked reduction of viable cell numbers in medulloblastoma cell lines and primary tumor cultures. Treatment of mice with D283 medulloblastoma xenografts with a gamma secretase inhibitor resulted in decreased proliferation and increased apoptosis, confirming that Notch signaling contributes to human medulloblastoma proliferation and survival. Medulloblastomas in ND2:SmoA1 mice and humans have concomitant increase in Shh and Notch pathway activities, both of which contribute to tumor survival.

Citing Articles

Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.

Holmberg K, Borgenvik A, Zhao M, Giraud G, Swartling F Cancers (Basel). 2024; 16(9).

PMID: 38730706 PMC: 11083189. DOI: 10.3390/cancers16091752.


Heterogeneity and tumoral origin of medulloblastoma in the single-cell era.

Sheng H, Li H, Zeng H, Zhang B, Lu Y, Liu X Oncogene. 2024; 43(12):839-850.

PMID: 38355808 PMC: 10942862. DOI: 10.1038/s41388-024-02967-9.


Chronic AMPK inactivation slows SHH medulloblastoma progression by inhibiting mTORC1 signaling and depleting tumor stem cells.

Malawsky D, Dismuke T, Liu H, Castellino E, Brenman J, Dasgupta B iScience. 2023; 26(12):108443.

PMID: 38094249 PMC: 10716552. DOI: 10.1016/j.isci.2023.108443.


Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.

Tu K, Stewart C, Williams N, Ma Y, Luo L, Ghosh D Radiat Res. 2023; 200(6):587-592.

PMID: 37990957 PMC: 11037923. DOI: 10.1667/RADE-23-00126.1.


-mediated overexpression leads to early death and severe cerebellar malformations with rare tumor formation.

Niesen J, Hermans-Borgmeyer I, Kruger C, Schoof M, Modemann F, Schuller U iScience. 2023; 26(9):107501.

PMID: 37608807 PMC: 10440564. DOI: 10.1016/j.isci.2023.107501.